LAMP1

Lysosome-associated membrane glycoprotein 1 · P11279 · LAMP1 on Sugi Atlas →

0 patent compounds predicted against LAMP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LAMP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia PHASE1/PHASE2NOT_YET_RECRUITING
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction EARLY_PHASE1RECRUITING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Natural History of Danon Disease nanCOMPLETED
The Natural History of Danon Disease nanUNKNOWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses nanCOMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN
Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM nanUNKNOWN
Danon Disease Natural History Study nanRECRUITING
Registry Gangliosidoses nanUNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
sCD163 in ALS Patients nanCOMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
Characterization of the Patient Population With Galactosialidosis nanCOMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Evaluation of HEArt invoLvement in Patients With FABRY Disease nanRECRUITING
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LAMP1 binder may also engage these)

ProteinNameSimilarity
P49129 0.995 P49129 →
Q05204 0.994 Q05204 →
P11438 0.992 P11438 →
P14562 0.991 P14562 →
P25291 0.944 P25291 →
P55259 0.942 P55259 →
Q6NW40 0.929 Q6NW40 →
A2AFS3 0.929 A2AFS3 →
Q6ZRP7 0.928 Q6ZRP7 →
Q7TQ33 0.926 Q7TQ33 →
Q9D806 0.926 Q9D806 →
Q29108 0.925 Q29108 →
Q0VBP7 0.922 Q0VBP7 →
Q5JXM2 0.921 Q5JXM2 →
Q3U0P5 0.920 Q3U0P5 →
Q3TMX7 0.920 Q3TMX7 →
Q8JG54 0.919 Q8JG54 →
E5RIL1 0.919 E5RIL1 →
Q6UW56 0.918 Q6UW56 →
A0A5B9 0.917 A0A5B9 →
Q9P0T7 0.917 Q9P0T7 →
ITGB8 Integrin beta-8 0.917 landscape →
Q62522 0.917 Q62522 →
B0FP48 0.917 B0FP48 →
Q9CR23 0.917 Q9CR23 →
P01850 0.916 P01850 →
Q96B86 0.916 Q96B86 →
Q9ER31 0.916 Q9ER31 →
Q3SXP7 0.916 Q3SXP7 →
P26013 0.915 P26013 →